Rituximab mabthera

Manufactured by Roche

Sourced in Switzerland

Rituximab/MabThera is a monoclonal antibody used in laboratory settings. It targets the CD20 antigen expressed on the surface of B cells. Rituximab/MabThera is widely used in research applications to study B cell biology and diseases involving B cells.

Automatically generated - may contain errors

Lab products found in correlation

Full length igg1 antibodies, by Miltenyi Biotec (1 mentions) Ez link nhs lc lc biotin, by Thermo Fisher Scientific (1 mentions) Pge1 oh, by Cayman Chemical (1 mentions) L 902 688, by Cayman Chemical (1 mentions)

Close spelling variants of this product

Rituximab (101 citations) MabThera (54 citations)

2 protocols using rituximab mabthera

Generation and Characterization of Adapter Antibodies

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the generation of anti-LAP adapter molecules (aLAP) full-length IgG1 antibodies (Miltenyi Biotec, clone: REA1214) were used. For the generation of anti-CD66c adapter molecules (aCD66c) full-length IgG1 antibodies (Miltenyi Biotec, clone: REA414) were used. For the generation of an anti-CD20 control adapter (aCD20) Rituximab/MabThera (Roche Pharma, PZN 8709896) was used. Conjugation of antibodies with EZ-Link™ NHS-LC-LC-Biotin (Thermo Fisher Scientific, catalog no.: 11841215) was done in PBS buffer at 20°C with a 3-fold molar excess of biotin for 1 h. Free LC-LC-biotin was removed via a Sephadex PD-10 G-25 column (Cytiva, catalog no.: 17085101). Conjugation was confirmed by LC-MS analysis.

Werchau N., Kotter B., Criado-Moronati E., Gosselink A., Cordes N., Lock D., Lennartz S., Kolbe C., Winter N., Teppert K., Engert F., Webster B., Mittelstaet J., Schaefer D., Mallmann P., Mallmann M.R., Ratiu D., Assenmacher M., Schaser T., von Bergwelt-Baildon M., Abramowski P, & Kaiser A.D. (2022). Combined targeting of soluble latent TGF-ß and a solid tumor-associated antigen with adapter CAR T cells. Oncoimmunology, 11(1), 2140534.

+ Open protocol

+ Expand

Monoclonal Antibody Procurement Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

PgE1-OH, L-902688 and PgE2 were obtained from Cayman Chemical, Ann Arbor, MI, USA. Rituximab (MabThera) was obtained from Roche, Basel, Switzerland, ofatumumab (Arzzera) from Novartis, Basel, Switzerland, obinutuzumab (Gazyva) from Genentech, South San Francisco, CA, USA and eculizumab (Soliris) from Alexion, Cheshire, CT, USA.

Markovič T., Podgornik H., Avsec D., Nabergoj S, & Mlinarič-Raščan I. (2022). The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies. International Journal of Molecular Sciences, 23(3), 1599.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!